Skip to main content
Andrew Geneslaw, MD, Pediatrics, New York, NY

Andrew Scott Geneslaw MD

Pediatric Critical Care Medicine


Physician

Join to View Full Profile
  • 3959 BroadwayNew York, NY 10032

  • Phone+1 212-305-5437

  • Fax+1 212-342-2293

Dr. Geneslaw is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Fellowship, Pediatric Critical Care Medicine, 2016 - 2019
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Chief Residency, Pediatrics, 2015 - 2016
  • New York Presbyterian Hospital (Columbia Campus)
    New York Presbyterian Hospital (Columbia Campus)Residency, Pediatrics, 2012 - 2015
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 2012

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2014 - 2025
  • Pediatrics
    American Board of Pediatrics Pediatrics
  • Pediatric Critical Care Medicine
    American Board of Pediatrics Pediatric Critical Care Medicine

Publications & Presentations

PubMed

Abstracts/Posters

  • Increased risk of mental disorder diagnoses associated with childhood invasive mechanical ventilation
    Geneslaw AS, Lu Y, Miles C, Hua M, Cappell C, Smerling A, Edwards JD, Ing C, Society for Critical Care Medicine Critical Care Congress 49, Orlando, FL, 2/16/2020

Press Mentions

  • Columbia Pediatrics Researchers Receive Seed Funding for Innovative Research
    Columbia Pediatrics Researchers Receive Seed Funding for Innovative ResearchFebruary 20th, 2020
  • Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale
    Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and RationaleMay 29th, 2020
  • A Step in De-MIS-Tifying MIS-C: The Importance of Early Immunomodulatory Therapy in MIS-C
    A Step in De-MIS-Tifying MIS-C: The Importance of Early Immunomodulatory Therapy in MIS-CAugust 5th, 2023

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: